Seulontaa

Seulontaa is a term from Finnish public health commonly translated as screening. It refers to the systematic process of identifying individuals in a population who do not yet have symptoms of a disease or condition but may be at risk, with the aim of enabling earlier detection, prevention, or intervention.

Screening is distinct from diagnosis. A Seulontaa program starts with defining a target population and selecting a screening test or method, which is followed by a threshold for further evaluation. Individuals who test positive typically undergo diagnostic testing to confirm the presence of disease. The goal is to reduce morbidity or mortality by catching conditions at a treatable stage while minimizing harms from unnecessary testing.

Effectiveness hinges on several factors, including disease prevalence, test sensitivity and specificity, and the uptake and follow-up rates within the population. High sensitivity reduces missed cases, while high specificity minimizes false positives. Programs must consider potential harms such as overdiagnosis, anxiety, overtreatment, and resource use, balancing them against potential benefits and costs.

Implementation generally proceeds through planning, pilot studies, and scaled rollout, with ongoing monitoring and quality assurance. Ethical considerations include informed consent, privacy, equitable access, and transparency about benefits and risks. Seulontaa is applied across domains such as cancer screening (for example, cervical, breast, and colorectal), newborn metabolic screening, infectious disease screening, and sensory or developmental assessments, reflecting its role in proactive public health and preventive medicine.